A rare pediatric patient of anti‐IgLON5 encephalitis with epileptic seizures as the first symptom

Jiao Xue,Zhenfeng Song,Hongshan Zhao,Zhi Yi,Fei Li,Chengqing Yang,Kaixuan Liu,Ying Zhang
DOI: https://doi.org/10.1002/jdn.10364
2024-07-15
International Journal of Developmental Neuroscience
Abstract:We described the second pediatric case with anti‐IgLON5 encephalitis, who was also the first presented with epileptic seizures as the initial presentation. For patients with new onset seizures associated with cognitive impairments and sleep disturbances, anti‐IgLON5 antibody should be tested as early, even in children. Background Anti‐IgLON5 encephalitis was a rare neurological and heterogeneous disorder, which was mainly found in adults. Epileptic seizures related to anti‐IgLON5 disease were rarely reported. Methods Neural antibodies associated with autoimmune encephalitis in serum and cerebrospinal fluid (CSF) were tested using cell‐based assays (CBA) with immunofluorescence double staining. The antibodies in serum were further confirmed by tissue‐based assay (TBA) with rat brain and kidney tissue. Results We reported a pediatric case presented with epileptic seizures, cognitive impairments, and sleep disorders. Autoantibody screening showed anti‐IgLON5 antibody IgG (1:100+) and anti‐NMDAR antibody IgG (1:10+) in the serum. She was diagnosed as anti‐IgLON5 encephalitis. Her conditions improved rapidly by treated with intravenous immunoglobulin and high dose intravenous methylprednisolone. Conclusion We described the second pediatric case with anti‐IgLON5 encephalitis, who was also the first presented with epileptic seizures as the initial presentation. Anti‐IgLON5 encephalitis might have mild manifestations. For patients with new onset seizures associated with cognitive impairments and sleep disturbances, anti‐IgLON5 antibody should be tested as early, even in children.
neurosciences,developmental biology
What problem does this paper attempt to address?